What is BioNTech
BioNTech SE (Biopharmaceutical New Technologies) is a Mainz-based German biotechnology firm that develops and manufactures active immunotherapies for patient-specific illness therapy. It develops individualized cancer immunotherapies, vaccines against infectious diseases, and protein replacement therapies for rare diseases based on messenger ribonucleic acid (mRNA), as well as engineered cell therapy, novel antibodies, and small molecule immunomodulators as cancer treatment options.
To deliver individualized mRNA-based cancer immunotherapy to clinical trials and establish its own manufacturing method, the business has developed an mRNA-based human therapeutic for intravenous injection.
BioNTech created the RNA vaccine BNT162b2 for preventing COVID-19 infections in 2020, in collaboration with Pfizer for testing and logistics. It has a 91 percent efficacy in preventing proven COVID-19 infections at least 7 days after the second dose of vaccine. The United Kingdom government granted interim HMR authorization for BNT162b2 immunizations within the United Kingdom on December 2, 2020. It was the first mRNA vaccination to be approved by the FDA. The vaccine was given emergency permission in the United States, Canada, and Switzerland a few days later. The European Commission authorized BioNTech/coronavirus Pfizer's vaccine on December 21, 2020, following the European Medicines Agency's favorable recommendation (EMA).
BioNTech is a publicly traded company, making its stock available to anyone of legal age interested in purchasing shares.
Why Buy BioNTech Shares (BNTX)
BioNTech shares represent a unit of ownership in BioNTech Inc. – and they are considered to be amongst the most traded financial instruments around the globe.
BioNTech shares will rise and fall in value according to how well the company is performing at a given moment in time. Better-than-expected earnings will make BioNTech share prices rise, while weaker earnings will make share prices fall. However, there are many reasons why a company's share price can change.
People trade BioNTech shares because, just like other financial instruments, they can be an opportunity to invest money. At a basic level, you can take a position on BioNTech shares to get exposure to economic growth. If an economy is in good shape, you might find that companies operating in that specific economic branch or industry will grow too.
Company growth is correlated with share price increases, which is what people are hoping for when they buy BioNTech shares.
CEO Uğur Şahin felt his company was one of the few that could quickly create an effective vaccine for what he feared would become a pandemic-level infection after reading an article about a mystery respiratory virus identified in Wuhan, China, three years ago. As that vaccine, now known as Comirnaty, was developed and tested with the support of its much larger partner, Pfizer, his exact prediction resulted in a 140 percent rise for shares in 2020. According to S&P Global Market Intelligence, the effective implementation of the vaccination boosted BioNTech stock by another 216 percent in 2021.
Analysts believe that BioNTech booked nearly $20 billion in revenue in 2021.
BioNTech stock is traded on the Nasdaq Stock Exchange under the BNTX ticker.
If all that makes you want in on BioNTech’s biotechnology growth, here is everything you need to know to buy BioNTech stock & shares to invest in BNTX.
How to Buy BioNTech Shares
Learning how to buy shares may not sound complicated, but you will need to do some research — and learn the basics — before making your first investment.
- Learn the difference between investing and trading
- Review BioNTech’s performance and outlook 2022
- Understand the risks and charges
- Access the trading platform and place your orders
- Stay up to date with the latest news and rumors about BioNTech
1. Learn the difference between investing and trading
People have two options to buy shares of stock online. Firstly, they can buy shares in companies on the exchanges where they are listed. For instance, you can buy BioNTech stock on the NASDAQ exchange, so you own a share in the company (investor). Alternatively, they can buy BioNTech shares without owning them, speculating on the price of the underlying asset (trader).
Investing and trading are similar terms that some people will sometimes use interchangeably – but there are significant differences for you to be aware of.
Investing in BioNTech Stock
Investors buy BioNTech shares hoping their price will rise and they can sell them later for a profit, adhering to the basic principle of buying low and selling high. Investors will take positions over a longer period, attempting to profit from share price changes as well as dividend payments.
While this means that they might need more initial capital to get started when compared to trading, their losses would be capped at this initial price tag. That said, investors should be aware they might get back fewer returns than they initially invested.
Investors will buy BioNTech shares to:
- Make a profit from the BioNTech share price rising
- Receive an income from dividends if the company pays them
- Benefit from the effects of compounding
This last point requires investors to hold onto their shares for an extended period. That’s why you’ll sometimes hear the phrase ”time in the markets is better than timing the markets” when talking about share investments.
>> Learn how to invest in stocks
BioNTech (or any single stock, for that matter) can be a very volatile investment. You can lower the risk by diversifying your investment holdings.
An index fund is a type of mutual fund or exchange-traded fund (ETF) with a portfolio constructed to match or track the components of a financial market index, such as the Standard & Poor's 500 Index (S&P 500). An index mutual fund provides a broad market exposure, low operating expenses, and low portfolio turnover. These funds follow their benchmark index regardless of the state of the markets.
BNTX currently makes about 1% of NASDAQ Biotechnology Index, meaning $0.01 of each dollar you invest in a NASDAQ Biotechnology Index fund goes to BioNTech.
Healthcare exchange-traded funds (ETFs) provide exposure to the performance of companies within the global software industry.
BNTX makes up 7.78% of MSGR (Direxion mRNA ETF), 4.45% of GERM (ETFMG Treatments Testing and Advancements ETF), 3.84% of HELX (Franklin Genomic Advancements ETF), 3.45% of APXH (APEX HealthCare ETF), 3.44% of BBH (VanEck Biotech ETF).
>> Learn what ETFs are and how do they work
Trading BioNTech CFDs
On the other hand, traders might seek to capitalize on short-term share price gains. Rather than investing in the shares, traders speculate on the shares’ value. They can speculate on it rising by going long, as well as falling by going short.
Trading BioNTech stock means that you are speculating on a share’s price movements with derivatives like CFDs. In other words, you are purchasing BioNTech shares without taking direct ownership.
Leverage is available when you use this product, giving you full market exposure for an initial deposit – known as margin – to open your position.
For example, a trader who wanted to buy 100 BioNTech shares CFD at $200.00 per share would only require $4,000 of trading capital, thereby leaving the remaining $16,000 available for additional trades.
But keep in mind that leverage can increase both your profits and your losses as they will be based on the full exposure of the trade, not just the margin requirement needed to open it. This means losses, as well as profits, could far exceed your margin.
With CFDs, you can ‘buy’ (go long) the shares if you think the BioNTech stock’s price will rise, or you can ‘sell’ (go short) if you think the BioNTech stock’s price will fall.
>> Learn what is CFD trading and how it works
Going Long BioNTech CFD
BioNTech has a sell price of $190.00 and a buy price of $190.60.
BioNTech’s next earnings announcement is fast approaching, and you expect it to be good news.
You think the company’s share price will go up, so you buy 100 BioNTech CFDs at $190.60 This is the equivalent of buying 100 BioNTech shares.
Because in CFD trading you can use leverage, you do not need to put up the full value of BioNTech shares. Instead, you only need to cover the margin, which is calculated by multiplying your exposure with the margin factor for the market you are trading.
So, if BioNTech has a margin factor of 20%, your margin would be 20% of the total exposure of your trade (100 share CFDs x $190.60 = $28,040), which is $3,812.
If your prediction is correct:
When BioNTech announces its results, it is clear the company had a successful quarter and as you had predicted, its share price climbs.
You decide to close your position when it reaches $215.20, with a buy price of $215.80 and a selling price of $215.20
You reverse your trade to close a position, so you sell your 100 CFDs for $215.20.
To calculate your profit, you multiply the difference between the closing price and the opening price of your position by its size. $215.20– $190.60 = $24.6, which you multiply by 100 CFDs to get a profit of $2460.
If your prediction is wrong:
BioNTech’s results are worse than expected, and its share price immediately falls. You decide to cut your losses and sell your 100 CFDs at $180.00.
Your position has moved $10.60 against you, meaning you suffer a loss of $1,060.
Going Short BioNTech CFD
Shorting with derivatives can be an effective way to protect your investments against downward price movements in your non-leveraged investment portfolio. Also, it can be a way to generate profits outright from shares that are falling in value. But when you go short, your potential losses are theoretically uncapped because there is no limit on how high a company’s share price can rise.
Here is an example:
Suppose BioNTech shares are currently trading with a selling price of $190.00, and you think the price will go down. So, you decide to open a short CFD position on 200 BioNTech shares CFD. A week later, the buy price reaches $172.40, and you close your position. This means you made $1,800 in profit ([190.00 - 172.40] x 200 = $3,520), excluding additional costs.
If the price rises, you register a loss. For example, if BioNTech shares rose to a price of $200.00, you would suffer a $2,000 loss instead, excluding additional costs.
When you create a trading account with CAPEX, you will be able to:
- ‘Buy’ (go long) or ‘sell’ (go short) BioNTech and other 2,000 international shares to speculate on their price rising or falling
- Take a position on our range of ETFs to get exposure to a basket of shares from an entire country, index, or sector that could be rising or falling in price.
- Trade a host of global indices to go long or short on the performance of an entire economy with a single trade.
- Use QuantX, the smart portfolio builder that helps you cover the popular industries and only invest in the top-performing stocks.
2. Review BioNTech’s Performance and Outlook 2022
Before buying BioNTech stock—or any stock (see our guide on how to buy shares)—it’s wise to do some research into the company’s financials, performance, and outlook. The easiest place to get started is through a company’s annual reports and quarterly reports. Public companies like BNTX are required to publicize detailed information about their financial health in these.
You can find these on BioNTech’s investor relations site or by searching the Securities and Exchange Commission’s (SEC) database.
You may also turn to experts for their input. Brokerage companies frequently release commentary on major stocks and industries, and third-party evaluators like Trading Central provide comprehensive technical and fundamental analysis.
When you combine financial data with expert insight, you will be able to decide how much of your money you want to put into BioNTech stock.
BioNTech Shares Forecast - Fundamental Outlook 2022
Before you load up the trunk with BioNTech shares, pop opens the hood and see what you are really getting into. Remember, when you buy BioNTech stock, you are purchasing a small portion of an actual business:
BioNTech builds and deploys operating systems for the modern enterprise.
BioNTech's balance sheet, income statement, competition, and management (all explained in our guide on how to research stocks) will help you give the company a good once-over.
You can access research, analyst ratings, and other key information about BioNTech via your brokerage account or a financial information website. If you like what you see, your next step is to consider whether BioNTech fits into your current investment portfolio.
BioNTech's market capitalization is $47.53B
- The Return On Assets for BNTX is 52.65%. This is one of the industry's finest returns. -31.93 percent is the industry average. BNTX surpasses 99 percent of its counterparts in the industry.
- BNTX has a Return On Equity of 86.02 percent, which is among the industry's top. BNTX surpasses 90% of its counterparts in the industry. The average return on equity in the industry is 14.89 percent.
- The profit margin for BNTX is 54.34 percent. This is one of the industry's finest returns. -393.66 percent is the industry average. BNTX surpasses 97 percent of its counterparts in the industry.
- BNTX's valuation may be classified as very cheap, with a Price/Earnings Ratio of 5.89.
- BNTX is valued slightly lower than its industry rivals, with an average Price/Earning Ratio of 16.00.
- The Forward Price/Earnings Ratio of 4.78 implies that BNTX is currently undervalued.
- The low PEG Ratio of BNTX, which accounts for growth in the Price/Earnings ratio, shows that the firm is undervalued.
- We can infer that BNTX is valued correctly when we compare its current price to its book value. It is currently trading at a price of 4.77 times its book value.
- When compared to the industry average price-to-book ratio of 2.26, BNTX is more costly than its peers.
- The Earnings Per Share of BNTX is increasing rapidly. The EPS has increased by 1752.27 percent in the last year, which is extremely amazing.
- BNTX is expected to increase at a very fast rate in earnings per share over the next five years, according to projections. On average, EPS will increase by 198.51 percent per year.
- The revenue of BNTX is increasing rapidly. Revenue has increased by 344.11 percent in the last year.
- The revenue of BNTX is increasing rapidly. Revenue has grown at a rate of 98.57 percent per year during the last five years.
- Revenue growth is predicted to be excellent for BNTX. Revenue will increase by 84.15 percent every year during the next five years.
- Revenue growth is expected to be consistent during the next five years.
- BNTX has a Current Ratio of 2.76, which suggests that it has no trouble meeting its short-term obligations.
The Quick Ratio of BNTX is 2.68. This shows that BNTX is financially sound and will be able to satisfy its short-term obligations with ease.
BNTX is in a poorer position to pay its short-term obligations than its industry rivals, with a Current Ratio of 8.14. The Current Ratio of 86 percent of its industry counterparts is higher.
*Last update: December 2021. Source: Yahoo Finance
BioNTech has never declared or paid a cash dividend and does not intend to pay.
BioNTech Shares Forecast - Technical Outlook 2022
Technical traders analyze price charts to attempt to predict price movement. The two primary variables for technical analysis are the time frames considered and the technical indicators that a trader chooses to utilize.
Our web-trading platform, for example, offers 6 chart types (including the famous Japanese candlestick chart) to help you analyze price performance across different timeframes. It also enables you to deal in an instant – directly from the charts. You will be able to open, close and edit positions in just a couple of clicks.
Trading charts always feature distinct patterns that technical analysts can use to interpret the behavior of buyers and sellers. These chart patterns can give traders an indication of where the market could go next. As you will notice when you look at a chart, the market will usually move in one overall direction or trend. There are three types of market trends: uptrends, downtrends, and sideways trends.
BioNTech stock has lost the July-August 2021 gains and is showing a classic A-B-C correction (see Elliott Wave theory).
The primary trend is bullish and the actual intermediate trend counter-trend could capitulate around $150. This BioNTech prediction is supported by the price trading below the previous low and 50-week Moving Average.
Bulls will wait for the lowest price that keeps the trend in a strong position and that should be a test of the trendline where BioNTech stock should show a base (double or triple top, inverse head & shoulders, or other reversal chart patterns) while technical indicators (RSI, MACD) should show a bullish divergence.
To buy BioNTech shares or not?
It is recommended to watch for stocks in the major long-term support area. We should buy BioNTech shares at relatively cheap prices (compared to historical values), not expensive prices. Also, have an exit plan for how you will exit a profitable trade. Define how and why you will exit. Since we used to support to get into the trade, you may consider exiting just below a long-term resistance level.
If buying at support, and planning to exit just below resistance, the upside potential should outweigh the downside risk by at least 2:1 or even 3:1. That means that if you buy BioNTech shares at $150, you should be reasonably able to get out of the stock at $125 or higher. In an absolute worst case you lose $25 a share, but based on the historical chart it is quite feasible to go up to $50/share or more. This is known as the risk/reward ratio, a key indicator when deciding to buy BioNTech shares or not.
With CAPEX WebTrader, you can perform an in-depth analysis of the charts with 90 indicators (including moving average, MACD, RSI, and Bollinger Bands). The platform also supports an interactive trading activity with high-end research tools helping you interpret market data.
Analyst consensus - BUY
The current consensus among 23 polled investment analysts is to buy BioNTech shares. The buy percentage consensus is 73%. So analysts seem to have mildly positive about BNTX.
- Strong Buy (4)
- Buy (8)
- Hold (10)
- Sell (1)
The price target on BioNTech (+66.76%)
The 23 analysts offering 12-month price forecasts for BioNTech have a median target of $326.86, with a high estimate of 472.50 and a low estimate of 181.80. This target is 66.76% above the current price.
3. Understand the risks and charges
Trading can be seen as riskier than investing due to leverage. But investing also carries a risk – and there is no guarantee that your investments would increase in value, so you could receive back less than you initially invested.
Before deciding to trade in shares, you should take steps to manage your risk. We have courses at CAPEX Academy that take you through risk management and how to mitigate your exposure to risk in the financial markets.
Our costs and charges for trading vary depending on the product that you use to take a position.
BioNTech (BNTX) CFD Trading Conditions
|SPREAD PER UNIT||0.11 pips||LEVERAGE||1:5|
|OVERNIGHT ROLLOVER - LONG||-0.0076 %||OVERNIGHT ROLLOVER - SHORT||-0.0063 %|
|INITIAL MARGIN||20.0000 %||MAINTENANCE MARGIN||10.0000 %|
- Spread represents the difference between ASK price and BID price.
- Future Rollover adjustment consists of the difference in price between expiring contract and new contract as well as the spread of the CFD.
- Swap is the amount credited to or debited from an account where positions are held overnight.
- Inactivity fee represents the monthly amount deducted if no activity is recorded for 12 months in an account.
4. Access the trading platform and place your orders
To buy BioNTech shares CFD with CAPEX Webtrader is very easy and intuitive. Opening an online trading account is as easy as setting up a bank account. Here are the steps:
Open an account or log in
First, create an account or log in on capex.com. To open an account, click the "Register" button and complete your details.
Once the platform is accessed, the registration process must be completed in order to operate with real money. Click "Complete the Registration and Start Trading".
To log in, from the CAPEX website, click on "Login".
Deposit funds into your account
To trade with a live account, it is necessary to deposit funds. This is done from the platform itself by clicking on the "Add funds" button:
Also, it is possible to trade on a risk-free demo account with a balance of € 50,000, which is ideal for getting to know the platform and testing trading strategies.
CAPEX offers you different payment methods: debit cards, credit cards, bank transfer, skrill, and more.
It is noteworthy that CAPEX does not charge any fees or commissions for depositing funds.
Look for BioNTech shares
To view BioNTech shares (BNTX) real-time price and chart on the trading platform can click on the "Search" icon located in the left panel or by clicking on "Shares" and then select the instrument, in this case, BioNTech.
Use the indicators and drawings to analyze the chart
Click the indicators icon and select your favorite ones. There are trend-following, oscillators, volatility, and support/resistance indicators available. To learn how many indicators to use and how to combine then visit the Technical Indicators section in CAPEX Academy.
Set up the order to buy BioNTech shares
To buy BioNTech shares CFD, click on the "Buy" button and a window is displayed to configure the purchase order:
The number of BioNTech shares to be purchased must be entered and it is allowed to set up a Stop Loss to limit the potential loss, and/or a Take Profit to close a profitable position once the BioNTech stock reaches a specific price. These orders can be configured based on price, pips, cash value, or percentage.
To proceed with the purchase, click on "Place Order".
However, BNTX trading does not end here. You will want to check out the next step to make sure you are investing your money as well as you can.
Why Trade BioNTech with CAPEX?
- Advanced AI technology at its core: Whether they prefer the web-based and mobile-ready WebTrader or favor the highly popular MetaTrader 5, we make sure investors make effective use of fast and reliable trade execution speeds, complex order and risk management tools, advanced charting options, powerful research tools in collaboration with highly-regarded platforms such as Trading Central or TipRanks.
- Trading on margin: Providing trading on margin (up to 5:1 for individual equities), CAPEX gives you access to the stock market with the help of CFDs.
- Trading the difference: When trading BioNTech CFD, you do not buy the underlying asset itself, meaning you are not tied to it. You only speculate on the rise or fall of the BioNTech stock price. Online trading with CFDs is nothing different from traditional trading in terms of strategies. A CFD investor can go short or long, set stop loss, take profit, and apply trading scenarios aligned with their objectives.
- All-round trading analysis: The browser-based platform allows traders to shape their market analysis and forecasts with sleek technical indicators. CAPEX provides live market updates and various chart formats, available on desktop, iOS, and Android.
- Focus on safety: capex.com is operated by Key Way Investments Ltd and is authorized and regulated by the Cyprus Securities and Exchange Commission (CySEC) (license no. 292/16).
- Global partnerships: CAPEX is proud to be the Proud Sponsor of Juventus, one of the most prestigious football clubs in the world, a football club that has a special place in the hearts of the people of Italy, with a strong legacy and a dedicated community.
5. Stay up to date with the latest news and rumors about BioNTech (BNTX)
Get the latest BioNTech (BNTX) stock news and headlines to help you in your trading and investing decisions.
History of BioNTech
BioNTech was created in 2008 with a seed investment of €150 million, based on research by Uğur Şahin, Özlem Türeci, and Christoph Huber. The company's efforts revolve around the research and manufacture of technology and pharmaceuticals for personalized cancer immunotherapy. Cofounders included Andreas and Thomas Strüngmann, Michael Motschmann, and Helmut Jeggle. The acquisition of EUFETS and JPT Peptide Technologies occurred in 2009. Katalin Karikó joined BioNTech as a senior vice president in 2013, after her work on mRNA at the University of Pennsylvania aided the development of the Pfizer–BioNTech COVID-19 vaccine.
BioNTech published a number of study findings on mRNA processes between 2014 and 2018. Beginning in 2015, different firms and research institutes entered into collaborations and commercialization efforts. BioNTech submitted multiple patent applications and created a multi-layered approach to protect its intellectual property in the various technology platforms and their use in the treatment of cancer and other critical diseases during this time.
In August 2018, the business announced a multi-year research and development (R&D) partnership with Pfizer Inc. of the United States to develop mRNA-based vaccines for influenza prevention. Pfizer will take entire responsibility for further clinical development and commercialization of mRNA-based flu vaccines after BioNTech completes a first-in-human clinical study, according to the conditions of the agreement.
Sanofi invested €80 million in BioNTech in January 2019, extending the two firms' mRNA cancer research relationship. In 2015, Sanofi paid US$60 million upfront for BioNTech's rights to five discovery-stage immunotherapies. The Bill & Melinda Gates Foundation gave BioNTech a capital contribution of US$55 million in September 2019, with the option to double that amount at a later date.
BioNTech has been publicly traded as American Depository Shares (ADS) on the NASDAQ Global Select Market under the ticker symbol BNTX since October 10, 2019, with its newly established North American headquarters in Cambridge, Massachusetts. The IPO brought in a total of $150 million in gross proceeds for BioNTech.
BioNTech stated in 2021 that it would establish its Asia headquarters in Singapore, as well as a vaccine manufacturing factory, with the help of the Singapore Economic Development Board. By 2023, the Singapore facility should be up and running, producing hundreds of millions of doses of mRNA vaccines every year. A plant in China will be built in partnership with Fosun Pharma to produce a billion doses per year for China, Macau, and Hong Kong.
*Last Update: December 2021. Source: Wikipedia